Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on ...

BeiGene, Ltd, a global oncology company that intends to change its name to BeOne Medicines Ltd., to unlock new insights in ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

Analysts have set 12-month price targets for BeiGene, revealing an average target of $330.25, a high estimate of $348.00, and a low estimate of $312.00. This current average reflects an increase of 10 ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Beigene (NASDAQ:ONC – Free Report) had its target price raised by JPMorgan Chase & Co. from $311.00 to $317.00 in a report published on Monday,Benzinga reports.JPMorgan Chase & Co. currently has ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

This obligation is derived from the “considerable effort” needed to demonstrate safety, quality and efficacy of an innovative ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...